PoniardPharmaceuticals, Inc. (Nasdaq: PARD), a specialty pharmaceutical companyfocused on oncology, today announced that the Company has completedenrollment in a Phase 2 open-label, multi-center clinical trial evaluatingpicoplatin for the treatment of small cell lung cancer (SCLC). All 75patients targeted for enrollment have been treated with picoplatin, theCompany's lead product candidate. [click link for full article]


Click Here to read the entire article...